Arch Biopartners Inc Sustainability Reports

Arch Biopartners Inc. is a clinical-stage biotechnology company focused on developing new drug candidates to treat organ inflammation, acute kidney injury, and complications arising from severe respiratory infections. Its lead drug candidate is LSALT peptide, which targets the Dipeptidase-1 (DPEP-1) pathway.

Sector: Manufacturing

Country: Canada

Exchange: OTC Markets

LEI: 984500E14QEB74DEE691

FIGI: BBG001SFS5M7

13 reports from 2013 to 2025

• Arch Biopartners Inc 2025 Consolidated Financial Statements
• Arch Biopartners Inc 2024 Consolidated Financial Statements
• Arch Biopartners Inc 2023 Consolidated Financial Statements
• Arch Biopartners Inc 2022 Consolidated Financial Statements
• Arch Biopartners Inc 2021 Consolidated Financial Statements